Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

BACKGROUND: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued Phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approac...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Beltran, Himisha, Wyatt, Alexander W, Chedgy, Edmund C, Donoghue, Adam, Annala, Matti, Warner, Evan W, Beja, Kevin, Sigouros, Michael, Mo, Fan, Fazli, Ladan, Collins, Colin C, Eastham, James, Morris, Michael, Taplin, Mary-Ellen, Sboner, Andrea, Halabi, Susan, Gleave, Martin E
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690882/
https://ncbi.nlm.nih.gov/pubmed/28842510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1034
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items